JP2021517156A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021517156A5 JP2021517156A5 JP2020552872A JP2020552872A JP2021517156A5 JP 2021517156 A5 JP2021517156 A5 JP 2021517156A5 JP 2020552872 A JP2020552872 A JP 2020552872A JP 2020552872 A JP2020552872 A JP 2020552872A JP 2021517156 A5 JP2021517156 A5 JP 2021517156A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- dose
- millikizumab
- maintenance dose
- maintenance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000012423 maintenance Methods 0.000 claims description 258
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 144
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 144
- 206010038063 Rectal haemorrhage Diseases 0.000 claims description 68
- 230000006698 induction Effects 0.000 claims description 56
- 230000001939 inductive effect Effects 0.000 claims description 45
- 239000003814 drug Substances 0.000 claims description 37
- 238000001802 infusion Methods 0.000 claims description 21
- 238000001990 intravenous administration Methods 0.000 claims description 21
- 238000010254 subcutaneous injection Methods 0.000 claims description 20
- 239000007929 subcutaneous injection Substances 0.000 claims description 20
- 238000012790 confirmation Methods 0.000 claims description 10
- 230000013872 defecation Effects 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- 241000193163 Clostridioides difficile Species 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims 36
- 239000000203 mixture Substances 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 71
- 238000001839 endoscopy Methods 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 229950009342 brazikumab Drugs 0.000 description 2
- 238000002052 colonoscopy Methods 0.000 description 2
- 229950010864 guselkumab Drugs 0.000 description 2
- 229950007943 risankizumab Drugs 0.000 description 2
- 229950005515 tildrakizumab Drugs 0.000 description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102000011718 Interleukin-23 Subunit p19 Human genes 0.000 description 1
- 108010076561 Interleukin-23 Subunit p19 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022123689A JP7331219B2 (ja) | 2018-03-30 | 2022-08-03 | 潰瘍性大腸炎を治療する方法 |
| JP2023130117A JP7571225B2 (ja) | 2018-03-30 | 2023-08-09 | 潰瘍性大腸炎を治療する方法 |
| JP2024176901A JP2025020134A (ja) | 2018-03-30 | 2024-10-09 | 潰瘍性大腸炎を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650314P | 2018-03-30 | 2018-03-30 | |
| US62/650,314 | 2018-03-30 | ||
| PCT/US2019/024633 WO2019191464A1 (en) | 2018-03-30 | 2019-03-28 | Methods of treating ulcerative colitis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022123689A Division JP7331219B2 (ja) | 2018-03-30 | 2022-08-03 | 潰瘍性大腸炎を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021517156A JP2021517156A (ja) | 2021-07-15 |
| JP2021517156A5 true JP2021517156A5 (cg-RX-API-DMAC10.html) | 2021-08-26 |
| JP7119114B2 JP7119114B2 (ja) | 2022-08-16 |
Family
ID=66429483
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020552872A Active JP7119114B2 (ja) | 2018-03-30 | 2019-03-28 | 潰瘍性大腸炎を治療する方法 |
| JP2022123689A Active JP7331219B2 (ja) | 2018-03-30 | 2022-08-03 | 潰瘍性大腸炎を治療する方法 |
| JP2023130117A Active JP7571225B2 (ja) | 2018-03-30 | 2023-08-09 | 潰瘍性大腸炎を治療する方法 |
| JP2024176901A Pending JP2025020134A (ja) | 2018-03-30 | 2024-10-09 | 潰瘍性大腸炎を治療する方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022123689A Active JP7331219B2 (ja) | 2018-03-30 | 2022-08-03 | 潰瘍性大腸炎を治療する方法 |
| JP2023130117A Active JP7571225B2 (ja) | 2018-03-30 | 2023-08-09 | 潰瘍性大腸炎を治療する方法 |
| JP2024176901A Pending JP2025020134A (ja) | 2018-03-30 | 2024-10-09 | 潰瘍性大腸炎を治療する方法 |
Country Status (29)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3972690A4 (en) | 2019-05-23 | 2023-07-05 | Janssen Biotech, Inc. | METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA |
| IL295545A (en) * | 2020-02-14 | 2022-10-01 | Janssen Biotech Inc | Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody |
| CA3183927A1 (en) | 2020-05-21 | 2021-11-25 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| JP7423815B2 (ja) * | 2020-10-20 | 2024-01-29 | セトラスホールディングス株式会社 | 治験管理装置、治験管理方法、治験管理プログラム及び治験管理システム |
| US20220259301A1 (en) * | 2021-01-06 | 2022-08-18 | Abbvie Inc. | Methods of treating crohn's disease and ulcerative colitis |
| BR112023024064A2 (pt) * | 2021-05-20 | 2024-01-30 | Janssen Biotech Inc | Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa |
| WO2022251623A1 (en) * | 2021-05-28 | 2022-12-01 | Eli Lilly And Company | Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis |
| KR20240103043A (ko) * | 2021-11-23 | 2024-07-03 | 얀센 바이오테크 인코포레이티드 | 항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법 |
| AU2023383916A1 (en) * | 2022-11-22 | 2025-07-10 | Janssen Biotech, Inc. | Method of treating ulcerative colitis with anti-il23 specific antibody |
| JP7863690B2 (ja) | 2023-03-10 | 2026-05-21 | イーライ リリー アンド カンパニー | 潰瘍性大腸炎を治療する方法 |
| JP2026521705A (ja) * | 2023-06-16 | 2026-07-01 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | 炎症性腸疾患の治療における組換え抗インターロイキン２３ｐ１９サブユニット抗体の使用 |
| AU2025218720A1 (en) | 2024-02-06 | 2026-05-21 | Paragon Therapeutics, Inc. | Il-23 antibody compositions and methods of use |
| WO2025171006A1 (en) | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 binding protein compositions and methods of use |
| WO2026060205A1 (en) | 2024-09-13 | 2026-03-19 | Eli Lilly And Company | PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2613818C (en) * | 2005-06-30 | 2013-08-27 | Centocor, Inc. | Anti-il-23 antibodies, compositions, methods and uses |
| SI3219328T1 (sl) | 2005-12-29 | 2020-10-30 | Janssen Biotech, Inc. | Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe |
| HUE042172T2 (hu) | 2007-02-23 | 2019-06-28 | Merck Sharp & Dohme | Genetikailag elõállított anti-il-23P19 antitestek |
| EP2352762A1 (en) * | 2008-11-03 | 2011-08-10 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| KR102049223B1 (ko) * | 2010-11-04 | 2019-11-28 | 베링거 인겔하임 인터내셔날 게엠베하 | 항－ｉｌ－２３ 항체 |
| JOP20140049B1 (ar) | 2013-03-08 | 2021-08-17 | Lilly Co Eli | أجسام مضادة ترتبط بـ il-23 |
| US20170002060A1 (en) * | 2014-01-08 | 2017-01-05 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
| JP7516250B2 (ja) * | 2018-03-05 | 2024-07-16 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｉｌ－２３特異的抗体を用いたクローン病の治療方法 |
-
2019
- 2019-03-27 TW TW108110767A patent/TWI744617B/zh active
- 2019-03-27 TW TW110139868A patent/TWI837532B/zh active
- 2019-03-28 EP EP25221972.0A patent/EP4752157A2/en active Pending
- 2019-03-28 PL PL23215626.5T patent/PL4327866T3/pl unknown
- 2019-03-28 SI SI201931019T patent/SI4327866T1/sl unknown
- 2019-03-28 IL IL312807A patent/IL312807B2/en unknown
- 2019-03-28 MD MDE20210135T patent/MD3773715T2/ro unknown
- 2019-03-28 CA CA3095297A patent/CA3095297A1/en active Pending
- 2019-03-28 FI FIEP23215626.5T patent/FI4327866T3/fi active
- 2019-03-28 MA MA52216A patent/MA52216B1/fr unknown
- 2019-03-28 EP EP23215626.5A patent/EP4327866B1/en active Active
- 2019-03-28 UA UAA202005571A patent/UA128578C2/uk unknown
- 2019-03-28 EA EA202091989A patent/EA202091989A1/ru unknown
- 2019-03-28 US US16/981,915 patent/US12152072B2/en active Active
- 2019-03-28 EP EP19722256.5A patent/EP3773715B1/en active Active
- 2019-03-28 IL IL277514A patent/IL277514B2/en unknown
- 2019-03-28 BR BR112020018099-8A patent/BR112020018099A2/pt not_active Application Discontinuation
- 2019-03-28 MA MA67901A patent/MA67901B1/fr unknown
- 2019-03-28 KR KR1020207027982A patent/KR102552693B1/ko active Active
- 2019-03-28 JP JP2020552872A patent/JP7119114B2/ja active Active
- 2019-03-28 DK DK19722256.5T patent/DK3773715T3/da active
- 2019-03-28 MY MYPI2020004942A patent/MY202368A/en unknown
- 2019-03-28 ES ES23215626T patent/ES3063700T3/es active Active
- 2019-03-28 LT LTEPPCT/US2019/024633T patent/LT3773715T/lt unknown
- 2019-03-28 HR HRP20240904TT patent/HRP20240904T1/hr unknown
- 2019-03-28 HU HUE19722256A patent/HUE067445T2/hu unknown
- 2019-03-28 MD MDE20241003T patent/MD4327866T2/ro unknown
- 2019-03-28 ES ES19722256T patent/ES2983809T3/es active Active
- 2019-03-28 RS RS20240698A patent/RS65661B1/sr unknown
- 2019-03-28 SG SG11202009526RA patent/SG11202009526RA/en unknown
- 2019-03-28 CN CN201980023563.3A patent/CN111936165A/zh active Pending
- 2019-03-28 SI SI201930750T patent/SI3773715T1/sl unknown
- 2019-03-28 AU AU2019243283A patent/AU2019243283C1/en active Active
- 2019-03-28 DK DK23215626.5T patent/DK4327866T3/da active
- 2019-03-28 PT PT197222565T patent/PT3773715T/pt unknown
- 2019-03-28 LT LTEP23215626.5T patent/LT4327866T/lt unknown
- 2019-03-28 FI FIEP19722256.5T patent/FI3773715T3/fi active
- 2019-03-28 PL PL19722256.5T patent/PL3773715T3/pl unknown
- 2019-03-28 MX MX2020010269A patent/MX2020010269A/es unknown
- 2019-03-28 PT PT232156265T patent/PT4327866T/pt unknown
- 2019-03-28 RS RS20260242A patent/RS67806B1/sr unknown
- 2019-03-28 WO PCT/US2019/024633 patent/WO2019191464A1/en not_active Ceased
- 2019-03-28 HR HRP20260275TT patent/HRP20260275T1/hr unknown
-
2020
- 2020-08-28 ZA ZA2020/05388A patent/ZA202005388B/en unknown
-
2022
- 2022-08-03 JP JP2022123689A patent/JP7331219B2/ja active Active
-
2023
- 2023-08-09 JP JP2023130117A patent/JP7571225B2/ja active Active
- 2023-10-11 AU AU2023248103A patent/AU2023248103B2/en active Active
-
2024
- 2024-10-09 JP JP2024176901A patent/JP2025020134A/ja active Pending
- 2024-10-16 US US18/917,597 patent/US20250034243A1/en active Pending
-
2026
- 2026-05-05 AU AU2026203410A patent/AU2026203410A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Auerbach et al. | Single-dose intravenous iron for iron deficiency: a new paradigm | |
| Hwang et al. | The role of endoscopy in the management of variceal hemorrhage | |
| Ralph et al. | Therapeutics for rheumatic fever and rheumatic heart disease | |
| Zhou et al. | A study evaluating ceftriaxone as a treatment agent for primary and secondary syphilis in pregnancy | |
| Smith | Repositioned drugs: integrating intellectual property and regulatory strategies | |
| Dutta et al. | Tolosa–Hunt syndrome: A review of diagnostic criteria and unresolved issues | |
| JP2016540785A5 (cg-RX-API-DMAC10.html) | ||
| JPWO2019107530A5 (cg-RX-API-DMAC10.html) | ||
| Cohen | Combined reduced-antigen content tetanus, diphtheria, and acellular pertussis (tdap) vaccine-related erythema nodosum: case report and review of vaccine-associated erythema nodosum | |
| Dorscheid et al. | Guidance for administering biologics for severe asthma and allergic conditions | |
| Alam et al. | Clinical impact of the early use of monoclonal antibody LY-CoV555 (bamlanivimab) on mortality and hospitalization among elderly nursing home patients: a multicenter retrospective study | |
| Sung | The role of acid suppression in the management and prevention of gastrointestinal hemorrhage associated with gastroduodenal ulcers | |
| Zhang et al. | Novel balloon compression-assisted endoscopic injection sclerotherapy and endoscopic variceal ligation in the treatment of esophageal varices: a prospective randomized study | |
| Pacheco et al. | Perianal disease in inflammatory bowel disease: Broadening treatment and surveillance strategies for anal cancer | |
| Matsuoka et al. | Treatment guidelines in inflammatory bowel disease: the Japanese perspectives | |
| Busse et al. | Pharmacological management of severe neuropathic pain in a case of eosinophilic meningitis related to Angiostrongylus cantonensis | |
| Kant | Do we have a magic bullet to treat moderate and severe anemia in pregnant women? | |
| CN106562967A (zh) | 一种治疗溃疡性结肠炎的药物组合物 | |
| Garg et al. | Antiviral drugs and vaccines for omicron variant: A focused review | |
| RU2015109933A (ru) | Композиции, включающие антитело и камостат мезилат (см) | |
| Hussar et al. | New drugs: Denosumab, dienogest/estradiol valerate, and polidocanol | |
| Wang et al. | A Case of Primary Refractory Immune Thrombocytopenia: Challenges in Choice of Therapies | |
| Peckham et al. | Antimicrobial stewardship can help prevent injection drug use related infections | |
| Bhadra et al. | Analysis of primary repair in cases of ocular dog bite injury: A case series | |
| JP2023512487A5 (cg-RX-API-DMAC10.html) |